Haloperidol is known as an antagonist of dopamine D2 receptors. It also blocks a variety of ion channels, however, at concentrations above the therapeutic range.
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Introduction
Haloperidol is commonly prescribed in clinical practice to treat psychiatric and neurologic diseases, and to control the symptoms of Tourette's syndrome. Its pharmacological effect is believed to be via the block of D2 dopamine receptors in the central nervous system (Seeman and Van Tol, 1994) . However, effects of haloperidol other than D2 receptor antagonism have been observed. Up-regulation of A-type potassium channel upon chronic haloperidol treatment has been proposed to suppress neuronal activity (Hahn et al., 2003) . Conversely, acute application of haloperidol has been reported to block numerous types of ion channels, including ATP-sensitive potassium channel (K ATP ) (Yang et al., 2004) , G-protein-activated inwardly rectifying potassium channel (GIRK) (Kobayashi et al., 2000) , and HERG potassium channels (Shuba et al., 2001 ). Drug-induced torsade de pointes, a lethal type of cardiac arrhythmia, has been correlated with blocking of the HERG channel by certain compounds, including haloperidol (Brown et al., 2004; Testai et al., 2004) . Therefore, understanding the basic mechanism of drug-channel interaction might provide a useful information for structurebased drug design (Fermini and Fossa, 2003) .
Potassium channels have been found in all known organisms and exhibit a high level of heterogeneity (Jan and Jan, 1997). Aberrant activity of potassium channels has been demonstrated in pathophysiological conditions, such as neurologic disorders, cardiac arrhythmia and diabetes (Shieh et al., 2000) . Therefore, the therapeutic and toxicologic aspects of drug-induced alterations in potassium channel activity are particularly relevant (Fermini and Fossa, 2003; Testai et al., 2004) . Delayed-rectifier potassium channels (K DR ) are characterized by slow opening and lack of a fast inactivation process. Because JPET #86561 of the nature of its kinetics, modification of K DR channel activity affects the shape and duration of action potentials (Bekkers, 2000) . Prolonged opening of the channels can lead to elevation of the local extracellular potassium concentration [ (Moulder et al., 2004) . On the other hand, [K + ] o also regulates potassium channel kinetics (Kuo, 1997) and interactions between drugs with ion channels can be modified at different [K + ] o (Kuo, 1998; Jo et al., 2000; Yang et al., 2004) .
In humans, haloperidol is metabolized via three major pathways. One metabolic route is oxidative N-dealkylation by cytochrome P450 and generates two metabolites, 4-chloro-4-hydroxypiperidine (4C4HP) and 3-fluorobenzoyl propionic acid (3FBPA). About 20% of haloperidol is degraded via this pathway. Another 50-60% of haloperidol is glucuronidated at the hydroxyl group and excreted in the urine. Alternatively, about 20-30% of haloperidol is reduced at the carbonyl group by ketone reductase and converted to reduced-haloperidol (R-haloperidol) (Froemming et al., 1989; Kudo and Ishizaki, 1999) .
R-Haloperidol is believed to have little clinical relevance since the binding affinity to D2
receptors is fairly low compared to haloperidol (Kirch et al., 1985) . However, its prolonged half-life and bigger volume of distribution (V d ) than haloperidol produces a substantial build-up of R-haloperidol in certain tissues (Korpi et al., 1984) . Since it can be oxidized back to haloperidol through the cytochrome P450 system, R-haloperidol has been proposed as an in vivo haloperidol reservoir (Kudo and Ishizaki, 1999) .
In this study, we investigated the effect of R-haloperidol and other chemically related compounds on K DR channels in mouse cortical neurons. We found that R-haloperidol is an open channel blocker for K DR channels. The binding site of R-haloperidol is located at JPET #86561 the K DR currents were elicited by 400 ms voltage steps from holding potential at -40 mV to +100 mV every 6 s. The capacitive transients were subtracted on-line by the P/4 method. All experiments were done at room temperature (20-25°C).
Solutions and chemicals
The extracellular solution contained (in mM): 150 NaCl, 10 HEPES, 5 KCl, 2 CaCl 2 , 1
MgCl 2 , and 5 4-aminopyridine (4-AP) with pH adjusted to 7.2 (by NaOH). In certain experiments, equimolar KCl or RbCl were used to replace NaCl, and pH was adjusted by adding KOH or RbOH, respectively. The intracellular solution contained (in mM): 150
KCl, 10 HEPES, 1 MgCl 2 , 5 Na 2 ATP, 5 EGTA, with pH adjusted to 7.2 (by KOH). 5 mM Na 2 ATP and 5 mM EGTA were added to block ATP-sensitive potassium currents (I KATP ) and Ca 2+ -activated potassium currents (I KCa ) (Speier et al., 2005) . Contamination by voltage-activated sodium and calcium currents at voltage-steps to +100 mV was negligible and therefore no blockers were added to the extracellular solution. KCl (150 mM) in the intracellular solution was substituted by equimolar RbCl in some experiments. In these experiments, a minimum of 2 min was used for dialysis to diminish the contamination with residual intracellular potassium ions. The osmolarity of all solutions was 300±10 mOsm l -1 . The recording chamber had a volume of 2 ml, and chemicals were focally applied to the cell through a self-made manifold pipe and driven by gravity with a flow rate of 5 ml min -1 .
L-741,626, sulpiride and loperamide were purchased from Tocris (Biotrend, Germany), 4-chloro-4-hydroxypiperidine was obtained from Alfa Aesar (Alfa Aesar, USA). All other chemicals were from Sigma (Sigma-Aldrich, Germany). Haloperidol, Rhaloperidol, 4-chloro-4-hydroxypiperidine, 3-fluorobenzoyl propionic acid, sulpiride and JPET #86561 9 predicted by using OSIRIS software (Actelion, UK). The pK a value of R-haloperidol was predicted by SciFinder database (CAS, USA).
Results
Separation of voltage-gated potassium currents in mouse cortical neurons
A large family of voltage-gated potassium channels are presented in mammalian neurons (Trimmer and Rhodes, 2004) . We used standard pharmacological method to isolate K DR currents by including 4-AP into the extracellular solution. Fig. 1A shows typical currents recorded from a cortical pyramidal neuron. The fast inactivating potassium currents (Atype K + currents) were suppressed by holding cells at -40 mV and adding of 4-AP to the extracellular solutions further decreased the peak currents (Fig. 1B) . The residual currents were insensitive to 4-AP and can be further blocked by tetraethylammonium extracellularly (data not shown), which resembles the typical K DR currents (Bekkers, 2000) . In order to reduce the contaminations of A-type potassium currents with minimum effects on K DR currents, 5 mM 4-AP was added into the extracellular solutions.
Block of K DR currents by haloperidol and its metabolites
We first examined the block of K DR current by haloperidol and its metabolites listed in Fig. 2A . Haloperidol blocked the K DR currents in a reversible manner (Fig. 2B) . The concentration-dependence curve was constructed by fitting data to the Hill equation ( 
This article has not been copyedited and formatted. The final version may differ from this version. where I drug and I control are the current amplitudes of the last 10 ms of the pulse (from 390 to 400 ms of the +100 mV voltage step) in the presence and absence of the drug, respectively, IC 50 is the half-maximal inhibitory concentration of the drug applied, and n is the slope parameter (Hill coefficient).
The metabolites of haloperidol were also examined in a similar manner. 4C4HP (Fig. 2D) and 3FPBA (Fig. 2E ), two metabolites generated by oxidative N-dealkylation, were much less potent than haloperidol. 3FPBA scarcely blocked the K DR . On the other hand, Rhaloperidol, a metabolite generated by carbonyl reduction, blocked the K DR currents to a similar degree as the parent compound ( Fig. 2F ). As R-haloperidol has higher concentrations in the human brain than haloperidol, we focused on this metabolite for the rest of the study.
Sidedness of R-haloperidol block
Potassium channels possess multiple drug binding sites and some are only accessible from one side of the plasma membrane. R-haloperidol is a tertiary amine, and it can either directly bind to its binding site from extracellular side or diffuse cross the plasma membrane and dock to the binding site on the cytoplasmic side (Hille, 1977) . To explore the sidedness of R-haloperidol binding, we synthesized N-methyl-reduced haloperidol (N-Me-R-haloperidol), the quaternary amine derivative of R-haloperidol (Fig. 3A) . Since it contains a permanent charge, it cannot cross the plasma membrane easily as its tertiaryamine-form when applied to either side of the membrane. Extracellular N-Me-Rhaloperidol only partially block the K DR current even at concentrations above 100 µM ( intracellular N-Me-R-haloperidol was so fast that the characteristic blocking kinetics can be observed in the first trace after the establishment of whole-cell configuration ( Fig.   3C ). Assuming N-Me-R-haloperidol binds to the same binding site as R-haloperidol, these experiments implied that R-haloperidol has to cross the membrane to access its binding site.
Voltage-dependence of R-haloperidol block
R-Haloperidol has a predicted pK a value of 8.5. In our standard extracellular solution (pH 7.2), about 95% of R-haloperidol was positively charged; thus, the membrane voltage can influence the binding of R-haloperidol if the binding site locates in the electric field (Garcia-Ferreiro et al., 2004) . To assess the voltage-dependent block of R-haloperidol on K DR currents, we used 400 ms voltage steps from -40 mV to potentials between +20 and +100 mV (Fig. 4A ). R-Haloperidol (10 µM) blocked these currents to a similar extent (Fig. 4B ). To quantify the voltage-dependence of the R-haloperidol block, the normalized currents were plotted against the membrane potential and fitted by the Woodhull equation (Choi et al., 2001) :
where [R-halop] is the concentration of R-haloperidol used (10 µM), IC 50 (0 mV) is the half-inhibition concentration of R-haloperidol at 0 mV, and δ is the fractional electrical distance from the external surface of the pore. F is the Faraday constant, V is the membrane potential, T is the absolute temperature, and R is the gas constant. A value of 25 was used for RT/F because the experiments were performed at room temperature (20 (Kuo, 1998; Boccaccio et al., 2004; Yang et al., 2004) . R-Haloperidol not only decreased the current amplitude, but also changed the kinetics by accelerating the current decay (Fig. 2F ). This implied that R-haloperidol preferentially
binds to an open state of the channels. We further analyzed the kinetics of the Rhaloperidol binding and the effect of external ions on the binding kinetics. Current traces at different R-haloperidol concentrations were point-by-point divided by the trace recorded in control conditions, and these normalized traces were fitted by a single
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k on and k off stand for the on-rate and off-rate of R-haloperidol to the potassium channels, and [R-Halop] is the concentration of R-haloperidol. (Fig. 6A ).
The intercept of the normalized current traces on the y-axis represents the fraction of channels blocked before they opened (Fig. 6A-D) . Therefore, the affinity of Rhaloperidol to the channels in the closed-state can be estimated by plotting the y-intercept versus R-haloperidol concentration. The apparent binding affinities to the channel in the closed-state were also decreased in the presence of extracellular potassium ions (Fig. 6G) .
Block of K DR channels by compounds functionally or structurally related to haloperidol
The backbone structure of R-haloperidol is similar to haloperidol, although the affinity to D2 receptor is reduced by about two orders of magnitude (Kirch et al., 1985; Froemming et al., 1989) . Thus, binding of R-haloperidol to K DR channels does not correlate to the D2 receptor potency. To address the active chemical moiety, several compounds with either functional or structural similarity were tested (Fig. 7A) . Sulpiride, another D2 receptor antagonist with similar potency as haloperidol but structurally unrelated, did not inhibit the potassium currents when applied extracellularly (Fig. 7B) . In contrast, L741-626, a D2 receptor antagonist with a similar chlorophenyl piperidine moiety, blocked the potassium currents to a similar extent as R-haloperidol ( Fig. 7C and D) . If the chlorophenyl piperidine moiety determines the block ability, other compounds with this fragment should also block the channels. Loperamide, an antidiarrheal drug that activates opioid receptors, also contains this fragment. We therefore tested if loperamide also blocked the K DR currents. To avoid the activation of opioid receptor, 10 µM naloxone was continuously present in the extracellular solution before and during the application of loperamide. K DR currents were not affected in the presence of 10 µM naloxone (data not shown). We found that loperamide was even more potent than other compounds tested, with an IC 50 value of 0.75 µM ( Fig. 7E and F) .
Discussion
In this study, we have shown that R-haloperidol, 
Binding site of R-haloperidol on the K DR channels
According to the scheme shown in Eq. (4) gate of potassium channels is located at the cytoplasmic end of the channel protein (Jiang et al., 2002) . Therefore, we propose that the binding site of R-haloperidol is either formed or accessible when the channel is opened. The quaternary amine binding has been located in the central cavity of the channel (Zhou et al., 2001 ), and we also have shown that the N-Me-R-haloperidol, the quaternary amine derivative of R-haloperidol, preferentially blocked the K DR currents from the intracellular side (Fig. 3) . The fractional electrical distance of 0.07 indicated a weak voltage-dependency of R-haloperidol block (Fig. 4) .
When the channel is in its open configuration, the voltage drops significantly across the
This article has not been copyedited and formatted. The final version may differ from this version. selective filter, and the central cavity is at the same membrane potential as the cytosolic solution (Jiang et al., 2002) . If the R-haloperidol binding site is in the central cavity and it is only accessible when the channel is open, it is plausible that the R-haloperidol block is independent of membrane voltage. Nevertheless, we cannot exclude the possibility that R-haloperidol blocks the channel in its neutral form.
Interaction of R-haloperidol and external cations on the K DR channels
Raising al. reported a similar phenomenon that K + but not Cs + regulates the binding of cisapride, a prokinetic compound, to HERG channels (Lin et al., 2005) . Nevertheless, the possibility of allosteric modulation of a channel by K + cannot be completely ruled out.
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Nature of the binding motif on R-haloperidol
The ability of compounds to block the K DR channels is dependent on the existence of the 4C4HP fragment, but not related to the pharmacological character of the compounds. We found a linear relationship between the logIC 50 and calculated the hydrophobicity index (clogP) in compounds containing the 4C4HP fragment (Fig. 8) . We proposed that the 4C4HP is the key fragment that binds to the K DR channel, and the affinity of 4C4HP is enhanced by adding a hydrophobic motif at the nitrogen atom on the piperidine ring, which increase the accessibility of 4C4HP to its intracellular binding site. On the other hand, increase of hydrophobicity also facilitates the binding of the active fragment to the receptor, and the hydrophobic motif functioned as a 'binder' of the active fragment. The binder concept was recently suggested in a fragment-based lead discovery, where the binding affinity is augmented by optimizing the binder part of the molecule (Rees et al., 2004) . It has been shown that increase of the hydrophobicity of quaternary amines enhance the binding affinity to its binding site (Choi et al., 1993) . The chemical nature of the binder can be unspecific, as the key fragment determines the main biological effect.
Therefore, it is worth checking the channel blocking ability of compounds with the 4C4HP motif at an early stage of drug development to avoid adverse effects caused by ion channel blocking (Fermini and Fossa, 2003) .
The oxygen atom in the carbonyl group has been proposed to involve the binding of haloperidol to the central cavity of HERG channels in an in silico study (Testai et al., 2004) . Most compounds listed in that study have already been reported as blockers for other potassium channels, including K DR channels. R-Haloperidol, in contrast, has a hydroxyl group at this position. Nevertheless, the binding affinities to the K DR channel of both R-haloperidol and haloperidol were comparable. It is likely the role of carbonyl oxygen was overestimated in the aforementioned in silico study (Testai et al., 2004) .
Therapeutic and toxicological relevance of R-haloperidol block on K DR channels
The plasma concentration of haloperidol and R-haloperidol is between 10 and 100 nM (Chang et al., 1989; Kudo and Ishizaki, 1999; Roh et al., 2001) , which is about two orders of magnitude below the IC 50 to block K DR channels. Our results indicated the block of K DR currents by haloperidol and/or R-haloperidol does not produce clinically relevant symptoms. However, in occasional cases, micromolar haloperidol and Rhaloperidol have been detected in human cortex (Korpi et al., 1984; Kornhuber et al., 1999) . A portion of potassium channels could be blocked under at these concentrations.
The local concentration of haloperidol and R-haloperidol cannot be predicted from the plasma haloperidol concentration, and haloperidol metabolism is variable among different individuals (Chang et al., 1989; Lam et al., 1995; Roh et al., 2001 ). Adverseeffects related to the R-haloperidol block of K DR channels can be expected, particularly when other drugs capable of modifying metabolic enzymes are co-prescribed (Kudo and Ishizaki, 1999) .
The loperamide block of K DR channel in cortical neurons should not be relevant because of the poor bioavailability and restricted blood-brain barrier penetration. The antidiarrheal effect of loperamide is suggested to be due to a decrease in the local ganglia activity in the enteric nervous system (Awouters et al., 1983) . Although the plasma concentration of loperamide is fairly low, in the nanomolar range, the local concentration in the gut may be much higher, due to the low solubility and enterohepatic shunt (Awouters et al., 1983) . Loperamide has been shown to decrease potassium efflux from epithelial cells, and direct block of potassium channels may be one explanation for this phenomenon (Epple et al., 2001) . Interestingly, haloperidol has already been shown to reduce the fluid secretion in rabbit and human small intestine mucosa, a property which is necessary for antidiarrheal treatment (Smith and Field, 1980 ).
In conclusion 
